Cargando…

Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications

The impaired ability to mount an effective immune response to vaccination leaves immunosuppressed patients at higher risk of severe COVID-19 infection. This retrospective study aimed to evaluate COVID-19 seroconversion and antibody titers for patients on immune modulating therapies compared to those...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levit, Elle, Longbrake, Erin E., Stoll, Sharon S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890787/ https://www.ncbi.nlm.nih.gov/pubmed/35276450 http://dx.doi.org/10.1016/j.msard.2022.103719

Ejemplares similares

A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies
por: Stoll, Sharon, et al.
Publicado: (2023)

Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
por: Longbrake, Erin E, et al.
Publicado: (2016)

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
por: Freeman, Léorah, et al.
Publicado: (2022)

An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis
por: Wu, Gregory F., et al.
Publicado: (2016)

Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
por: Maglione, Alessandro, et al.
Publicado: (2022)

Seroconversion in household members of COVID-19 outpatients
por: Cox, Rebecca J, et al.
Publicado: (2021)

COVID19 seroconversion in an unrelated stem cell donor
por: Maakaron, Joseph E., et al.
Publicado: (2020)

Brainstem lesions are associated with sleep apnea in multiple sclerosis
por: Levit, Elle, et al.
Publicado: (2020)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2022)

To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England
por: Tugemann, Bastian, et al.
Publicado: (2022)

COVID-19 Seroconversion in Emergency Professionals at an Urban Academic Emergency Department in New York City
por: Jeong, Jordan M., et al.
Publicado: (2020)

Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies
por: Wallach, Asya I., et al.
Publicado: (2022)

Multiple drugs: No Seroconversion and vaccine failure: 2 case reports
Publicado: (2022)

Awareness of patients with multiple sclerosis in Saudi Arabia regarding the relationship between smoking and multiple sclerosis
por: Kashoo, Faizan Z., et al.
Publicado: (2020)

Seroconversion after influenza vaccination in patients with lung cancer
por: Anderson, H, et al.
Publicado: (1999)

Predictors of seroconversion after coronavirus disease 2019 vaccination
por: Chiarella, Sergio E., et al.
Publicado: (2022)

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
por: Bollo, Luca, et al.
Publicado: (2020)

COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
por: Gelibter, Stefano, et al.
Publicado: (2021)

Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
por: Krbot Skorić, Magdalena, et al.
Publicado: (2022)

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
por: Weberpals, Janick, et al.
Publicado: (2022)

Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients
por: Georgieva, Zoya G, et al.
Publicado: (2021)

Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
por: Jack, Dominic, et al.
Publicado: (2020)

Successful seroconversion following mild COVID-19 contraction in a double-vaccinated B-cell-depleted person with multiple sclerosis: A hint towards booster efficacy?
por: Etemadifar, Masoud, et al.
Publicado: (2021)

CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome
por: Choileáin, Siobhán Ní, et al.
Publicado: (2019)

Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
por: Shen, Yandong, et al.
Publicado: (2022)

Characteristics of COVID-19 disease in multiple sclerosis patients
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Multiple Manifestations of Systemic Sclerosis Affect Walk Distance
por: Andréasson, Kristofer, et al.
Publicado: (2021)

Seroconversion and dynamics of the anti-SARS-CoV-2 antibody response related to a hospital COVID-19 outbreak among pediatric oncology patients
por: Mayanskiy, Nikolay, et al.
Publicado: (2021)

COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID
por: Fiorella, Celsi, et al.
Publicado: (2020)

Seroconversion after COVID-19 vaccine in a dialysis patient on immunosuppressants
por: Alfano, Gaetano, et al.
Publicado: (2021)

Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency
por: Squire, Jacqueline, et al.
Publicado: (2021)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

COVID-19 in a temporal relation to the onset of multiple sclerosis
por: Fragoso, Yara D., et al.
Publicado: (2021)

Predictors Of Seroconversion Following COVID-19 Vaccination
por: Chiarella, Sergio, et al.
Publicado: (2022)

Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
por: Türkoğlu, Recai, et al.
Publicado: (2022)

Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches
por: Grand′Maison, Francois, et al.
Publicado: (2018)

COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
por: Fernández-Díaz, Eva, et al.
Publicado: (2020)

The lateralization of clinical findings might not affect the clinical outcome in multiple sclerosis
Publicado: (2020)

COVID-19 vaccine efficacy data: solid enough to delay second dose? – Authors' reply
por: Amit, Sharon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ail38pa4fdmepg93l4ato2k9bb